Eli Lilly and Company News - August 28, 2026

Lilly's Heart-Shield Label for Mounjaro Closes a Key Gap With Ozempic — But Can a $10 Billion Drug Still Grow Into Its Price?
LLY

Lilly's Heart-Shield Label for Mounjaro Closes a Key Gap With Ozempic — But Can a $10 Billion Drug Still Grow Into Its Price?

Shares of Eli Lilly ticked up 0.6% to $1,183.14 Thursday after the FDA approved its blockbuster diabetes drug Mounjaro to reduce the risk of heart attack,...
Eli Lilly's Mounjaro Wins FDA Approval to Lower Heart Risks in Diabetes
LLY

Eli Lilly's Mounjaro Wins FDA Approval to Lower Heart Risks in Diabetes

The FDA approved Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes. This...